A physician who prescribes both said tirzepatide is more effective for cravings specifically, while semaglutide also reduces overall intake. AUDIT score reductions in his clinic are comparable.
Another member raised a practical point: patients eat less on both drugs, so when they do drink, they reach higher blood alcohol levels faster.
Asked whether the brand matters (Mounjaro, Zepbound or semaglutide), the group agreed the molecule matters more than the label. Tirzepatide's dual GIP and GLP-1 action may explain the stronger effect on cravings, though there are no head-to-head data in alcohol use disorder.
A member also flagged two interactions from recent literature: hypercalcemia risk with thiazide diuretics or calcium supplements, and higher lithium levels in patients on lithium.
Key takeaways
- Tirzepatide may have an edge for cravings; both reduce intake.
- Warn patients who drink that they may become intoxicated faster.
- Check for thiazide, calcium and lithium interactions.
- Head-to-head data are still needed.
From Buzz in the chat, the longevitydocs™ Sunday newsletter, May 17, 2026. Member discussion, not clinical guidance.
Originally published in The Longevity Medicine Intelligence newsletter.
